A Retrospective Analysis of PK and Response of Oral Ibuprofen in the Treatment of a Patent Ductus Arteriosus in Extremely Low Gestational Age Neonates.

Mohd Asif, Katelyn Sushko, Abdul Razak, Sayem Borhan, Michael Rieder, John van den Anker, Samira Samiee-Zafarghandy

Abstract read

In one paragraph

Article in Journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohd AsifNeonatal Intensive Care Unit, McMaster Children's Hospital, Hamilton, ON, Canada.

Katelyn SushkoFaculty of Health Sciences, School of Nursing, McMaster University, Hamilton, ON, Canada.

Abdul RazakDepartment of Pediatrics, Monash University, Melbourne, VIC, Australia.

Sayem BorhanDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.

Michael RiederDepartment of Physiology & Pharmacology and Medicine (MR), University of Western Ontario, London, ON, Canada.

John van den AnkerDivision of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA.

Samira Samiee-ZafarghandyNeonatal Intensive Care Unit, McMaster Children's Hospital, Hamilton, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral ibuprofen is the preferred pharmacotherapeutic option for treatment of a persistent patent ductus arteriosus (PDA), but evidence for its optimal use in extremely low gestational age newborns (ELGANs) remains limited. In the current study, we aimed to investigate the pharmacokinetics and exposure-response relationship of oral ibuprofen in ELGANs of ≤72 h postnatal age (PNA) on standard (SD) versus those >72 h PNA on high-dose (HD) regimen for closure of persistent PDA. This was a retrospective analysis of data from a previous population PK study of ELGANs with a persistent PDA treated with a SD (10-5-5 mg/kg/day, PNA <72 h) versus a HD (20-10-10 mg/kg/day, PNA >72 h) oral ibuprofen, with the primary aim of comparing degree of exposure, defined as AUC

Indexed as

Anti-Inflammatory Agents, Non-SteroidalDuctus Arteriosus, PatentIbuprofenAdministration, OralArea Under CurveDose-Response Relationship, DrugFemaleGestational AgeHumansInfant, Extremely PrematureInfant, NewbornMaleRetrospective StudiesAnti-Inflammatory Agents, Non-SteroidalIbuprofenadverse eventsoral ibuprofenpharmacokineticspreterm neonate

Identifiers

PMID40237626

DOI10.1002/jcph.70033

PMCPMC12397716

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.